SL-279252 |
TAK-252; SL-279252 |
Phase 1 Clinical |
Shattuck Labs |
Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
INSIX RA (Indus Biotech) |
|
Clinical |
Indus Biotech Pvt Ltd |
Arthritis, Rheumatoid; Inflammation |
Details
|
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase 2 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
PD-1 knockout engineered T cells (Chengdu MedGenCell) |
|
Phase 2 Clinical |
West China Hospital Of Sichuan University, Chengdu Medgencell |
Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
RB-0004 |
RB-0004 |
Phase 1 Clinical |
Reyoung Pharmaceutical Co Ltd |
Solid tumours; Lymphoma |
Details
|
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell |
Details
|
HX-009 |
HX-009 |
Phase 1 Clinical |
Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd |
Liver Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) |
SG-001 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Lymphoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
CX-188 |
|
Phase 1 Clinical |
Cytomx Therapeutics |
Neoplasms |
Details
|
Nivolumab/Relatlimab |
BMS-986213; BMS-936558/BMS-986016 |
Phase 3 Clinical |
Bristol-Myers Squibb Company |
Stomach Neoplasms; Melanoma |
Details
|
Sym-021 |
Sym-021 |
Phase 1 Clinical |
Symphogen |
Lymphoma; Neoplasm Metastasis |
Details
|
MGD-019 (MacroGenics) |
MGD-019 |
Phase 1 Clinical |
Macrogenics |
Colorectal Neoplasms |
Details
|
Budigalimab |
ABBV-181 |
Phase 1 Clinical |
Abbvie Inc |
Ovarian Neoplasms; Head and Neck Neoplasms; HIV Infections; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) |
|
Phase 2 Clinical |
Anhui Kedgene Biotechnology, Hangzhou Cancer Hospital |
Esophageal Neoplasms |
Details
|
W0180 |
|
Phase 1 Clinical |
Pierre Fabre Medicament |
Neoplasms |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) |
|
Phase 1 Clinical |
Anhui Anke Biotechnology (Group)Co Ltd |
Esophageal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms |
Details
|
RO-7247669 |
RO-7247669 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Programmed cell death 1 antibody (Sun Yat-sen University) |
|
Phase 2 Clinical |
Sun Yat-Sen University |
Carcinoma, Hepatocellular |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) |
|
Phase 1 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours |
Details
|
PD-1 knockout EBV-CTL (Nanjing Medical University) |
|
Phase 2 Clinical |
Nanjing Medical University |
Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma |
Details
|
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) |
|
Phase 2 Clinical |
Chongqing Xinqiao Hospital |
Squamous Cell Carcinoma of Head and Neck |
Details
|
IBI315 |
IBI315; IBI-315 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Hanmi Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
ONO-4685 |
ONO-4685 |
Phase 1 Clinical |
Merus |
Autoimmune Diseases |
Details
|
T3011疱疹病毒(深圳市亦诺微医药) |
|
Phase 1 Clinical |
Shenzhen Yinuowei Pharmaceutical Technology Co Ltd |
Head and Neck Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Shandong Xinshidai Pharmaceutical) |
|
Phase 2 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Lymphoma, T-Cell, Peripheral; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms |
Details
|
MEDI-5752 |
MEDI-5752 |
Phase 1 Clinical |
Medimmune Llc |
Carcinoma, Renal Cell; Neoplasms |
Details
|
YBL-006 |
YBL-006; YBL 006 |
Phase 1 Clinical |
|
Solid tumours; Neoplasms |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
BCD-217 |
BCD-217 |
Phase 2 Clinical |
Biocad |
Melanoma |
Details
|
PD-1 knockout engineered T cells (Cell Biotech) |
|
Phase 1 Clinical |
Cell Biotech |
Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Sinocelltech) |
SCT-I10A |
Phase 3 Clinical |
Shenzhou Cell Engineering Co Ltd |
Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular |
Details
|
IMU-201 |
IMU-201 |
Phase 1 Clinical |
Imugene |
Carcinoma, Non-Small-Cell Lung |
Details
|
609-A (SBio) |
609-A |
Phase 1 Clinical |
Shenyang Sunshine Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) |
|
Phase 1 Clinical |
Shanxiweiqidaguangming Pharmaceutical Co Ltd |
Solid tumours |
Details
|
XmAb20717 |
XmAb-20717 |
Phase 1 Clinical |
Xencor |
Astrocytoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Thymoma; Colorectal Neoplasms; Carcinoma, Renal Cell; Prostatic Neoplasms; Vulvar Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Mesothelioma; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell |
Details
|
MiHA-loaded PD-L silenced DC vaccination (Radboud University) |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin |
Details
|
TY-101 |
TY-101; TY101 |
Phase 2 Clinical |
Tayu Huaxia Biotech Medical Group Co Ltd |
Solid tumours; Neoplasms; Lymphoma |
Details
|
RO-7121661 |
RG-7769; RO-7121661 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) |
|
Phase 1 Clinical |
Beijing Mali Biotechnology Co Ltd, Chengdu Yinhe Biomedicine Co Ltd |
Lymphoma, B-Cell |
Details
|
IBI318 |
IBI-318; LY-3434172; LY3434172 |
Phase 2 Clinical |
Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd |
Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
CMAB-819 |
CMAB8-19 |
Phase 1 Clinical |
Sinomab Bioscience Ltd |
Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
GNR-051 |
GNR-051 |
Phase 1 Clinical |
Generium Pharmaceuticals |
Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
CA-170 |
CA-170; AUPM-170 |
Phase 2 Clinical |
Aurigene |
Solid tumours; Neoplasms |
Details
|
CC-90006 |
C-90006; CC-90006 |
Phase 1 Clinical |
Anaptysbio |
Autoimmune Diseases; Psoriasis |
Details
|
MEDI-0680 |
AMP-514; MEDI-0680 |
Phase 2 Clinical |
Medimmune |
Kidney Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell |
Details
|
Pidilizumab |
CT-011; MDV-9300 |
Phase 2 Clinical |
Curetech |
Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Multiple Myeloma; Lymphoma, Follicular; Prostatic Neoplasms; Hepatitis C; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Glioma; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic |
Details
|
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) |
|
Phase 1 Clinical |
Hengrui Yuanzheng Biotechnology Co Ltd |
Solid tumours; Stomach Neoplasms |
Details
|
Recombinant human anti-PD-1 monoclonal antibody(Yiyi Health Technology) |
|
Phase 1 Clinical |
Shanghai Yunyi Health Technology Development Co Ltd |
Neoplasms |
Details
|
MK-4280A |
MK-4280A |
Phase 1 Clinical |
Moshadong R & D (China) Co Ltd, Msd Ireland (Carlow) Merck Sharp & Dohme Corp |
Solid tumours |
Details
|
Balstilimab |
AGEN2034; RebmAb-700 |
Phase 2 Clinical |
Ludwig Institute For Cancer Research, Agenus Inc |
Hemangiosarcoma; Uterine Cervical Neoplasms |
Details
|
AK-112 |
AK-112 |
Phase 2 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Solid tumours; Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
Cetrelimab |
JNJ-3283; JNJ-63723283 |
Phase 3 Clinical |
Johnson & Johnson |
Carcinoma, Transitional Cell; Multiple Myeloma; Urinary Bladder Neoplasms |
Details
|
MAX-10181 |
MAX-10181; MAX-1 |
Phase 1 Clinical |
Guangzhou Maxinovel Pharmaceiticals Co Ltd |
Solid tumours |
Details
|
INCB-086550 |
INCB-086550 |
Phase 2 Clinical |
Incyte Corp |
Solid tumours; Carcinoma; Carcinoma, Renal Cell; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
ONCR-177 |
ONCR-177 |
Phase 1 Clinical |
Oncorus |
Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Skin Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
9MW1111 |
9MW1111 |
Phase 1 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Solid tumours |
Details
|
Tebotelimab |
PD-1 X LAG-3; MGD-013 |
Phase 3 Clinical |
Macrogenics |
Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Breast Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular |
Details
|
JTX-4014 (Jounce Therapeutics) |
JTX-4014 |
Phase 2 Clinical |
Jounce Therapeutics |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
AK-104 |
AK-104 |
Phase 2 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Lymphoma, T-Cell, Peripheral; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Nasopharyngeal Carcinoma; Microsatellite Instability; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma |
Details
|
Retifanlimab |
INCMGA-0012; INCMGA-00012; MGA-012 |
Phase 3 Clinical |
Macrogenics |
Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Solid tumours; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Anus Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms |
Details
|
Sasanlimab |
RN-888; PF-6801591; PF-06801591 |
Phase 3 Clinical |
Pfizer Pharmaceuticals Ltd (China) |
Pancreatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Bile Duct Neoplasms; Sarcoma; Prostatic Neoplasms; Urinary Bladder Neoplasms; Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms |
Details
|
AMG-404 |
AMG-404 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms |
Details
|
XmAb-23104 (Xencor) |
|
Phase 1 Clinical |
Xencor |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Sarcoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
BI-754091 |
BI-754091 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Solid tumours; Head and Neck Neoplasms; Rectal Neoplasms; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
Spartalizumab |
PDR-001 |
Phase 3 Clinical |
Novartis Pharma Ag |
Sarcoma, Alveolar Soft Part; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Primary Myelofibrosis; Bone Marrow Diseases; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Chordoma; Endometrial Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Persistent Fetal Circulation Syndrome; Adenocarcinoma; Stomach Neoplasms; Ovarian Neoplasms; Solid tumours; Leukemia; Leukemia, Myeloid; Head and Neck Neoplasms; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Liver Neoplasms; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Thyroid Carcinoma, Anaplastic; Pancreatic Neoplasms; Neoplasms, Squamous Cell; Small Cell Lung Carcinoma; Myelodysplastic Syndromes; Digestive System |
Details
|
LZM-009 |
LZM-009 |
Phase 2 Clinical |
Livzon(Group) Pharmaceutical Factory |
Thymoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) |
BAT-1306 |
Phase 2 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms |
Details
|
STW204单抗 |
STW-204 |
Phase 1 Clinical |
Suzhou Stainwei Biotech Inc |
Solid tumours |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody(Akeso Biopharma) |
AK-103; HX-008 |
Phase 3 Clinical |
Zhongshan Akeso Biopharma Co Ltd, Taizhou Hanzhong Biomedical Co Ltd, Hangzhou Hansi Biomedicine Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Thyroid Carcinoma, Anaplastic; Triple Negative Breast Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Gastrointestinal Neoplasms |
Details
|
CS-1003 |
CS-1003 |
Phase 3 Clinical |
Cstone Pharmaceuticals |
Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular |
Details
|
HLX-10 |
HLX-10 |
Phase 3 Clinical |
Shanghai Henlius Biotech Co Ltd |
Solid tumours; Head and Neck Neoplasms; Liver Neoplasms; Hepatitis B, Chronic; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Microsatellite Instability; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
Recombinant human PD-1 antibody herpes simplex virus |
|
Phase 1 Clinical |
Yangshengtang Co Ltd, Xiamen University |
Liver Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Melanoma |
Details
|